LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

LIDCOrapid v2 with continuous non-invasive blood pressure cleared for sale in Japan

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces the LiDCOrapidv2 with Unity software and continuous non-invasive blood pressure module have been cleared for sale in Japan.

LiDCO's Unity software allows the connection of LiDCO's continuous non-invasive blood pressure monitoring module. Existing LiDCOrapid monitors can be easily upgraded to provide the new functionality. LiDCO believes that the availability of the Company's Unity software and continuous non-invasive blood pressure module will double the numbers of surgery patients suitable for monitoring with LiDCO's technology.

Japan is the second largest market in the world for hemodynamic monitoring. The Company estimates that there are approximately 680,000 high-risk surgical patients per annum in Japan who can now benefit clinically from improved intraoperative fluid management.

Commenting, Terry O'Brien, Chief Executive Officer of LiDCO, said: "We expect the availability of this new product to significantly expand the market potential for sales of our monitors and associated high margin disposables in Japan. With this registration we believe that our non-invasive monitor can now address fluid and drug management across the entire surgical patient pathway without the insertion of minimally invasive arterial catheters."

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

*BISTM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.